Compare BioNTech SE - ADR (BNTX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Tripadvisor Inc Common Stock — how do they compare? BioNTech SE - ADR trades at $92.57 (market cap $23.31B), while Tripadvisor Inc Common Stock trades at $10.54 (market cap $1.28B). The key difference: BioNTech SE - ADR is far larger — about 18.2× Tripadvisor Inc Common Stock's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| BNTX | TRIP | |
|---|---|---|
Market Cap | $23.31B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $19.14 |
52-Week Low | $83.89 | $9.24 |
Enterprise Value | $6.60B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Tripadvisor (TRIP) trades at $10.78, flat on the day, with a bearish technical signal but bullish oscillators. The company reported Q2 2026 EPS of $0.35, missing estimates, though revenue reached $1.89B in 2025 with a net income margin of 2.11%. Recent news highlights competitive pressures from AI travel tools and the pending $700M sale of TheFork to American Express, providing a cash infusion.
Outlook remains mixed; the stock is undervalued on P/S (0.72) but carries a high P/E (127.18). Risks include stiff competition and earnings misses, yet analyst consensus targets $13.29, suggesting 23% upside. Investor sentiment is cautious, with 62.5% hold ratings, but Viator's U.S. leadership offers a growth avenue amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
